Glaucoma, retina, and ophthalmic industry topics kickstart the ASCRS and ASOA Annual Meetings

# Top Glaucoma and Retina Trends at ASCRS & ASOA Annual Meetings

The ASCRS & ASOA Annual Meetings are among the most anticipated events in ophthalmology, bringing together leading experts to discuss groundbreaking advancements in eye care. This year, the spotlight was on glaucoma and retina treatments, with innovative technologies, surgical techniques, and pharmaceutical developments taking center stage.

In this article, we’ll explore the top trends and breakthroughs from the meetings, providing insights into the future of glaucoma and retina care.

## **1. Advances in Glaucoma Treatment**

### **Minimally Invasive Glaucoma Surgery (MIGS) Continues to Evolve**
One of the most discussed topics was the refinement of Minimally Invasive Glaucoma Surgery (MIGS). These procedures are gaining traction due to their safety profile and effectiveness in reducing intraocular pressure (IOP).

Key highlights included:
–

**New MIGS devices** – Several next-generation stents and implants were showcased, offering better outcomes with fewer complications.

–

**Combination therapies** – Surgeons are increasingly pairing MIGS with cataract surgery for enhanced results.

–

**Long-term efficacy data** – Studies confirmed sustained IOP reduction over several years, reinforcing MIGS as a viable first-line option.

### **Artificial Intelligence (AI) in Glaucoma Diagnosis**
AI-powered diagnostic tools are transforming glaucoma detection and monitoring. Presentations highlighted:
–

**Automated visual field analysis** – AI algorithms now provide faster, more accurate interpretations of visual field tests.

–

**OCT imaging enhancements** – Machine learning improves the detection of early structural changes in the optic nerve.

## **2. Breakthroughs in Retina Care**

### **Gene Therapy for Inherited Retinal Diseases**
Gene therapy is revolutionizing the treatment of inherited retinal disorders like Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). Key takeaways included:
–

**FDA-approved therapies** – Updates on existing treatments and their real-world outcomes.

–

**Emerging gene-editing techniques** – CRISPR-based approaches show promise in preclinical studies.

### **Extended-Release Drug Delivery Systems**
Chronic retinal conditions like diabetic macular edema (DME) and wet AMD require frequent injections, but new sustained-release options aim to reduce treatment burden:
–

**Port Delivery Systems (PDS)** – Implants that release anti-VEGF drugs over several months.

–

**Biodegradable implants** – Eliminate the need for surgical removal.

### **AI and Imaging in Retinal Diagnostics**
AI is also making waves in retina care, with advancements in:
–

**Automated OCT analysis** – Faster detection of fluid and structural abnormalities.

–

**Predictive analytics** – Identifying high-risk patients before vision loss occurs.

## **3. Surgical Innovations in Glaucoma and Retina**

### **Micro-Invasive Techniques for Glaucoma**
Surgeons are adopting ultra-precise tools for safer procedures:
–

**Microcatheter-assisted trabeculotomy** – Improves outflow with minimal trauma.

–

**Laser-assisted procedures** – Selective laser trabeculoplasty (SLT) is becoming more refined.

### **Robotic-Assisted Retinal Surgery**
Robotics is enhancing precision in vitreoretinal surgery:
–

**Improved maneuverability** – Allows for delicate maneuvers in complex cases.

–

**Reduced surgeon fatigue** – Enhances procedural consistency.

## **4. Pharmaceutical Developments**

### **Novel Glaucoma Medications**
New drug classes are expanding treatment options:
–

**Rho kinase inhibitors** – Offer additional IOP-lowering mechanisms.

–

**Neuroprotective agents** – Aim to preserve optic nerve function beyond IOP control.

### **Next-Generation Anti-VEGF Therapies**
The retina space saw updates on:
–

**Biosimilars** – Cost-effective alternatives to traditional anti-VEGF drugs.

–

**Dual-action drugs** – Targeting multiple pathways for improved efficacy.

## **5. Patient-Centric Approaches**

### **Telemedicine and Remote Monitoring**
The rise of telehealth in ophthalmology was a recurring theme:
–

**Home-based tonometry** – Devices allowing patients to monitor IOP remotely.

–

**Virtual consultations** – Expanding access to specialist care.

### **Personalized Treatment Plans**
With genetic testing and AI, doctors can now tailor therapies to individual patient profiles.

## **Conclusion**

The ASCRS & ASOA Annual Meetings showcased a wave of innovation in glaucoma and retina care, from AI-driven diagnostics to gene therapy and robotic surgery. These advancements promise to enhance patient outcomes, reduce treatment burdens, and pave the way for a new era in ophthalmology.

Stay tuned as these trends continue to shape the future of eye care!